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Abstract
Background: Timely vaccination is important to induce adequate protective immunity. We measured vaccination
timeliness and vaccination coverage in three geographical areas in South Africa.
Methods: This study used vaccination information from a community-based cluster-randomized trial promoting
exclusive breastfeeding in three South African sites (Paarl in the Western Cape Province, and Umlazi and Rietvlei in
KwaZulu-Natal) between 2006 and 2008. Five interview visits were carried out between birth and up to 2 years of
age (median follow-up time 18 months), and 1137 children were included in the analysis. We used Kaplan-Meier
time-to-event analysis to describe vaccination coverage and timeliness in line with the Expanded Program on
Immunization for the first eight vaccines. This included Bacillus Calmette-Guérin (BCG), four oral polio vaccines and
3 doses of the pentavalent vaccine which protects against diphtheria, pertussis, tetanus, hepatitis B and
Haemophilus influenzae type B.
Results: The proportion receiving all these eight recommended vaccines were 94% in Paarl (95% confidence
interval [CI] 91-96), 62% in Rietvlei (95%CI 54-68) and 88% in Umlazi (95%CI 84-91). Slightly fewer children received
all vaccines within the recommended time periods. The situation was worst for the last pentavalent- and oral polio
vaccines. The hazard ratio for incomplete vaccination was 7.2 (95%CI 4.7-11) for Rietvlei compared to Paarl.
Conclusions: There were large differences between the different South African sites in terms of vaccination
coverage and timeliness, with the poorer areas of Rietvlei performing worse than the better-off areas in Paarl. The
vaccination coverage was lower for the vaccines given at an older age. There is a need for continued efforts to
improve vaccination coverage and timeliness, in particular in rural areas.
Trial registration number: ClinicalTrials.gov: NCT00397150
Background
Timely vaccination is important to induce adequate
immunity [1-3]. Delayed immunisation is a risk factor
for pertussis, measles and Haemophilus influenzae type
B disease [1,2,4,5]. Late administration of the Bacillus
Calmette-Guérin (BCG) vaccine is also associated with
reduced survival [6].
Some studies have shown that good vaccination cover-
age for individual vaccines does not necessarily imply
timely vaccination [3,7-11]. There may also be non-speci-
fic effects of vaccines that can be influenced by timeli-
ness, with potential negative consequences of delayed
immunisation [12,13]. Thus, it is important to take time-
liness into account, as relying only on vaccination status
can lead to a false assumption of adequate vaccination.
Although some studies have evaluated timely vaccina-
tion of some selected vaccines, we are only aware of two
published studies from the United States and Uganda
where the timeliness of all nationally recommended vac-
cines has been evaluated [10,11]. Only two other studies
have assessed timely vaccination for some selected vac-
cines in African settings [9,14]. There also seems to be
conflicting information in South Africa between the
nationally reported morbidity related to vaccine preven-
table diseases compared to reports about large measles
outbreaks [15,16]. In this study, we assessed immunisa-
tion timeliness and vaccination coverage for the first
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eight vaccines of the Expanded Program on Immuniza-
tion (EPI) in South Africa. This included BCG (Bacillus
Calmette-Guérin), four doses of oral polio vaccines and
three doses of the pentavalent vaccine protecting against
diphtheria, pertussis, tetanus, hepatitis B and Haemophi-
lus influenzae type B disease.
Methods
This study used vaccination information from the com-
munity-based cluster-randomized PROMISE-EBF trial
promoting exclusive breastfeeding by peer-counsellors
in three South African sites between 2006 and 2008
(ClinicalTrials.gov no: NCT00397150) [17]. A total of 34
clusters from three separate areas in South Africa were
chosen: Paarl in Western Cape Province (peri-urban),
and Umlazi (peri-urban) and Rietvlei (rural) in Kwa-
Zulu-Natal Province. The infant mortality rate (IMR) in
Paarl is about 40/1000, and the antenatal HIV-preva-
lence was 10% at the time of the study [18]. The IMR in
Umlazi was around 60/1000 and the antenatal HIV-pre-
valence 42%. The poor and rural area Rietvlei had an
IMR of 99/1000 and an antenatal HIV-prevalence of
34% at the time of the study.
Some of the, mothers approached for study participa-
tion in the PROMISE-EBF study were excluded due to
an intention to formula feed (142). They were enrolled
in the Good start Study [19]. Both the participants in
the PROMISE-EBF study and the Good Start Study pro-
vided information on vaccination. A total of 1276
mother-infant pairs were recruited from both of the stu-
dies. Among these, 139 were excluded due to relocation
or being lost-to-follow-up, twin delivery, death of the
infant or mother before 3 weeks after birth, or severe
malformations (additional file 1, figure S1). Thus, 1137
mother-infant pairs remained in the analysis. The
mother-infant pairs were scheduled to be interviewed at
3, 6, 12 and 24 weeks after birth, with an additional fol-
low-up interview between 18 and 24 months of age.
Most vaccination information was collected during the
last two visits. Vaccination information was collected
from the last two visits. A health card was seen for 935
(98%) among those who were interviewed at 24 weeks
when much of the vaccination information was gath-
ered. These health cards were dated, but in some
instances the date was invalid. The median follow-up
time was 18 months.
Data management
Data was collected through interviews by trained data
collectors, and subsequently entered using EpiData
(http://www.epidata.dk). Data analysis was done with
Stata version SE11.1 (Stata Corporation).
Vaccination timeliness and coverage
The Expanded Program on Immunization in South
Africa recommended the following vaccines to be given
at specific ages during the study period in line with the
recommendations from the World Health Organisation
(time ranges given in parentheses) [9,20]:
○ The first vaccination visit is at birth when the
BCG (birth-8 weeks) and oral polio (birth-4 weeks)
vaccines are given.
○ The following three vaccination visits include the
oral polio vaccine and a pentavalent vaccine which
protects against diphtheria, tetanus and pertussis
(DTP), Haemophilus influenzae type B (Hib) disease
and hepatitis B (HBV). The first dose is given at 6
weeks (4 weeks-2 months), then again at 10 weeks
(8 weeks-4 months), and at 14 weeks (12 weeks-6
months).
○ The measles vaccine is given at 9 months (38
weeks-12 months).
○ At 18 months, a booster dose was given with pro-
tection against measles, polio, diphtheria, pertussis
and tetanus. The recommended time range of the
booster vaccination has not been clearly defined.
○ In 2009 (after completed data collection), a rota-
virus and a 7-valent pneumococcal vaccine were
added to the program.
Vaccines given outside these ranges will be referred to
as untimely vaccinations.
Analysis
With the exceptions of measles and booster vaccines,
vaccination timeliness was analysed with Kaplan-Meier
time-to-event analysis in line with Laubereau et al. [21].
Coverage was determined at the end of follow-up. Vac-
cination data were gathered from the children’s health
cards. When vaccinations were registered without a
valid date, we assumed that the age when the children
were given the specific vaccines was similar to the age
of those who had their vaccinations dated (around 2%
had missing dates for each vaccine). The confidence
intervals (CI) were estimated with Greenwood’s point-
wise method. The timing of measles and booster vac-
cines is presented with histograms. Due to a question
that was missed out in the questionnaire, we had to
make an assumption whether the reported timing of the
measles vaccine was either the first measles vaccine or
the booster vaccine. We assumed that vaccinations
received before 12 months of age were the first dose of
measles vaccine, and vaccinations after 12 months were
booster vaccinations. Due to the structural weaknesses
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in the recording of measles vaccination in this study, the
information on measles vaccination must be interpreted
with care.
To investigate determinants of timely vaccination, we
used a cluster adjusted Cox regression analysis. The Cox
regression assumption of proportional hazards was
checked with Schoenfeld residuals, both graphically and
with a significance test. Tied cases were handled with
the exact partial-likelihood method. Rational interactions
were evaluated. Log linearity was checked by plotting of
Martingale residuals for the complete model vs. a model
with one omitted variable. We present univariable and
multivariable models for both coverage at the end of fol-
low-up and timeliness. The multivariable analyses used a
stepwise selection with removal of covariates when p >
0.1. The models were adjusted for cluster.
Socioeconomic wealth index was constructed with the
use of multiple correspondence analysis based on own-
ership of assets as mobile phone and television, and
house characteristics including water source, roof mate-
rial and toilet type. This method is analogous to princi-
pal component analysis, and better suited for categorical
data [22]. The children’s families were grouped into
quintiles on the basis of socioeconomic rank.
Ethics
Ethical approval was granted by Ethics Committee of
the Medical Research Council South Africa, and Regio-
nal Committees for Medical and Health Research Ethics,
Western Norway. Signed or thumb-printed informed
consent was obtained from each mother prior to study
participation.
Results
There were large variations between the three sites in
vaccination coverage and timeliness, both for the indivi-
dual vaccines and all the first eight vaccines assessed
together, table 1, figures 1, 2 and 3. The timing of the
individual vaccines and the timing of all vaccines pre-
sented with hazard plot are available as additional files
2, 3, 4, 5, 6, 7, 8, 9 and10 (figures S2, S3, S4, S5, S6, S7,
S8, S9 andS10).
The proportion of children receiving all of the first eight
recommended vaccines were 94% in Paarl (95%CI 91-
96), 88% in Umlazi (95%CI 84-91) and 62% in Rietvlei
(95%CI 54-68). Fewer children received all vaccines
within the recommended time period, 88% in Paarl
(95% confidence interval 84-91), 79% in Umlazi (95%CI
74-82) and 58% in Rietvlei (95%CI 51-64). Nearly all
untimely vaccinations were given too late.
The coverage was lowest for the last oral polio vaccine
with a coverage rate of 87% (95%CI 85-89) for all sites
combined, and for the last pentavalent vaccine with
coverage of 88% (95%CI 86-90). Rietvlei had the lowest
coverage also for these vaccines.
Among the children above 12 months of age, 669
(86%) had received at least one measles vaccine. The
time for the measles vaccination was distributed around
the recommended time period of 38 weeks, figure 3.
The distribution of booster vaccination was around 18
months with a small amount of scattering.
Determinants of incomplete and untimely vaccination
The mean level of education among the mothers was 10
years of schooling in Paarl, 11 years in Umlazi and 9
years in Rietvlei. The socioeconomic situation was dif-
ferent in the 3 sites, reflected in 328 (94%) having elec-
tricity in Paarl, 446 (93%) in Umlazi, and 185 (61%) in
Rietvlei.
No interactions were significant and meaningful in
magnitude compared to the individual factors. No com-
bination variables had correlation values above 0.7. The
Cox regression models revealed a strong association
between geographical site and both incomplete vacci-
nated at the end of follow-up and untimely vaccination,
table 2. The hazard ratio (HR) for incomplete vaccinated
was 7.2 (95%CI 4.7-11) for Rietvlei compared to Paarl.
The association between geographical site and untimely
vaccination was slightly weaker, with a HR 3.3 (95%CI
2.3-4.7) for Rietvlei compared to Paarl.
The children being delivered at home or children with
several siblings also had a higher risk of incomplete and
untimely vaccination. Socioeconomic factors were also
strongly associated with timely vaccination and vaccina-
tion coverage in the univariable analysis, but was nearly
nullified when including geographical site in the model.
A site stratified analysis confirmed that socio-economy
within the site was not associated with vaccination cov-
erage in Rietvlei and Umlazi, but an association was
seen in Paarl (data not shown).
Breastfeeding peer-counselling was also associated
with vaccination coverage, with higher coverage among
children receiving peer-counselling on breastfeeding and
children of mothers who intended to formula feed.
Discussion
This study revealed substantial differences in vaccination
between the different geographical sites. There was a 7
fold hazard ratio of not being vaccinated at the end of
follow-up for Rietvlei compared to Paarl. Rietvlei is a
poor and rural area, but adjusting for socio economic or
other factors did not alter the association substantially.
This is consistent with other studies in these three
populations which have shown strong geographic differ-
ences in health services quality and health outcomes
[19].
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The nationally reported coverage rates for the third
doses of the HBV and Hib vaccines in 2004 were 92%
and 93%, respectively [23]. This is somewhere between
the estimates for Paarl and Umlazi that is reported in
this study for the third dose of the corresponding penta-
valent vaccine in this study, but much higher than the
coverage rates in the poor area Rietvlei.
The differences between vaccination coverage and vac-
cination timeliness were not as large for most vaccines
in this study compared to what has been observed in
some other studies [3,7-10]. This means that most of
those who were vaccinated, received their vaccines
within the recommended time period. Still, the
proportion who received their vaccines later than
recommended for the second and third vaccination vis-
its was substantial. In general, the factors associated
with good vaccination coverage were the factors that
were associated with timely vaccination.
Although it is difficult to assess the timeliness and
coverage of measles vaccination from this study, the
trend with increasingly lower coverage for the later vac-
cinations compared to the earlier vaccinations, indicate
that the situation for the measles vaccine is likely to be
worse than for the last pentavalent and oral polio vac-
cines. Currently, the South African vaccination program
has included the rotavirus and pneumococcal vaccines,
Table 1 Coverage and timeliness of vaccines in the South African EPI program.
Site Coverage
(end of follow-up)
Timely vaccination Given too early Given too late Not given
(at end of follow-up)
Polio 0 Paarl 99 (96-100) 99 (96-100) 0 (0-0) 0 (0-0) 1 (0-4)
Umlazi 100 (98-100) 99 (97-100) 0 (0-0) 1 (0-1) 0 (0-2)
Rietvlei 99 (96-100) 94 (91-97) 0 (0-0) 4 (3-6) 1 (0-4)
Total 100 (99-100) 97 (96-98) 0 (0-0) 3 (2-3) 0 (0-1)
BCG vaccine Paarl 99 (97-100) 99 (97-100) 0 (0-0) 0 (0-0) 1 (0-3)
Umlazi 100 (98-100) 100 (98-100) 0 (0-0) 0 (0-0) 0 (0-2)
Rietvlei 99 (97-100) 99 (97-100) 0 (0-0) 0 (0-0) 1 (0-3)
Total 99 (98-100) 99 (98-100) 0 (0-0) 0 (0-0) 1 (0-2)
Polio 1 Paarl 100 (98-100) 92 (90-93) 1 (0-2) 7 (5-8) 0 (0-2)
Umlazi 99 (98-100) 88 (86-89) 1 (0-3) 10 (8-12) 1 (0-2)
Rietvlei 96 (92-98) 72 (67-75) 1 (0-4) 22 (19-25) 4 (2-8)
Total 99 (98-99) 85 (84-87) 1 (1-2) 12 (11-14) 1 (1-2)
DPT1+Hib+HBV Paarl 100 (98-100) 93 (90-94) 0 (0-2) 6 (4-8) 0 (0-2)
Umlazi 99 (98-100) 88 (86-89) 1 (1-3) 10 (8-12) 1 (0-2)
Rietvlei 97 (95-99) 77 (73-79) 2 (1-4) 19 (16-21) 3 (1-5)
Total 99 (98-100) 87 (85-88) 1 (1-2) 11 (10-12) 1 (0-2)
Polio 2 Paarl 99 (97-100) 94 (92-94) 1 (0-2) 4 (3-5) 1 (0-3)
Umlazi 98 (96-99) 90 (87-91) 0 (0-2) 8 (6-9) 2 (1-4)
Rietvlei 87 (82-91) 72 (67-75) 1 (0-3) 14 (12-14) 13 (9-18)
Total 96 (94-97) 87 (85-88) 1 (0-1) 8 (7-9) 4 (3-6)
DPT2+Hib+HBV Paarl 99 (97-100) 95 (93-95) 0 (0-2) 3 (2-4) 1 (0-3)
Umlazi 98 (96-99) 90 (88-91) 0 (0-2) 7 (6-8) 2 (1-4)
Rietvlei 92 (88-95) 80 (75-82) 0 (0-3) 12 (10-13) 8 (5-12)
Total 97 (96-98) 90 (88-91) 0 (0-1) 7 (6-8) 3 (2-4)
Polio 3 Paarl 94 (91-96) 93 (91-94) 1 (0-3) 0 (0-0) 6 (4-9)
Umlazi 98 (96-99) 87 (83-88) 0 (0-2) 11 (9-13) 2 (1-4)
Rietvlei 69 (62-75) 64 (57-71) 0 (0-0) 5 (4-5) 31 (25-38)
Total 87 (85-89) 84 (82-86) 0 (0-1) 2 (2-3) 13 (11-15)
DPT3+Hib+HBV Paarl 94 (91-96) 92 (90-93) 1 (0-3) 0 (0-0) 6 (4-9)
Umlazi 90 (87-93) 86 (83-88) 0 (0-2) 4 (3-4) 10 (7-13)
Rietvlei 74 (68-80) 70 (64-73) 0 (0-3) 4 (4-4) 26 (20-32)
Total 88 (86-90) 85 (83-86) 1 (0-1) 3 (3-3) 12 (10-14)
Coverage at end of follow-up and the proportion receiving the vaccinations within the recommended time periods (timely vaccination) are presented with 95%
confidence intervals. Similarly, untimely vaccination are categorised into vaccines given earlier or later than recommended. Rates given for each of the three sites
and in total
* The pentavalent vaccine (DPT1+Hib+HBV) protects against diphtheria, pertussis, tetanus, Haemophilus influenzae type b and hepatitis B
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which have a potential to avert a large number of child
deaths [24]. These vaccines are supposed to be given
together with the pentavalent and measles vaccines.
Thus, sub-optimal vaccination with for example the
third pentavalent vaccine is likely to be associated with
unsatisfactory vaccination also with the rotavirus and
pneumococcal vaccines. To get optimal protection from
these vaccines, good vaccination coverage and timeliness
are essential [25,26].
Globally there have been gradual improvements in
vaccination coverage, with large reductions in measles,
pertussis and tetanus mortality. Still, these diseases were
responsible for about 4% of the global child mortality
according to a systematic analysis from 2008 [15]. The
same report attributed few deaths in South Africa to
these diseases, with only one pertussis death, one
measles death, and 139 deaths from tetanus. This is
likely to be an underestimate, considering the relatively
low coverage rates we observed in Rietvlei for the vac-
cines given earlier than the measles vaccine, in addition
to large measles outbreaks in South Africa, including an
extensive national outbreak reported in June 2010 [16].
More than 15 000 cases with measles and 18 confirmed
deaths were report from this source.
Most deaths from diseases with available vaccines are
preventable, and diseases such as measles and polio can
be eliminated with vaccination [27-29]. To accomplish
this, a high vaccination coverage rate is needed [30,31].
The vaccination coverage in this study was inadequate
particularly for the later vaccines in some of the areas,
and several children were also vaccinated too late, leaving
them susceptible to diseases when their maternal antibo-
dies have declined to levels insufficient to protect them
[1-3]. For some vaccines including the BCG vaccine, late
Figure 1 Time when receiving vaccines given in the four first vaccination visits for each site presented with inverse and cumulative
Kaplan-Meier plots . In the first vaccination visit, an oral polio vaccine (polio0) is given together with the BCG vaccine, in the second, third and
fourth vaccination visits, pentavalent vaccines are given together with polio vaccines. (Larger versions of the graph images are available as
additional files 3, 4, 5, 6, 7, 8, 9 and10.) 1 The blue vertical lines indicate the recommended age for vaccination (overlapping with red lines at
birth for BCG and first polio vaccine), while the red lines indicate the outer ranges for the recommended age. The horizontal dotted lines
represent coverage at end of follow-up. 2 The labels on the x-axis indicate the outer ranges for recommended vaccination age. One year of age
is indicated as a scaling, but is also the upper recommended age for the measles vaccine. 3 Blue graphs line: Paarl; green graph line: Umlazi; red
graph line: Rietvlei.
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administration has been associated with higher mortality
[6]. In this study, nearly all received the BCG and first
oral polio vaccine soon after birth. There is also a lack of
evidence on potential indirect effects of timing of immu-
nisation outside the recommended time ranges [12].
The presence of the measles booster vaccine in the
South African immunisation program offers some insur-
ance if children are either vaccinated earlier than recom-
mended or miss the first measles vaccine [30,32-34].
One of the associations that was found in this study was
a lower risk of incomplete vaccination among those who
had an intention to formula feed. This might be a reflec-
tion that many of these children have HIV-positive
mothers, and they might be followed up more closely,
also with respect to vaccination of their children. For
children infected with HIV, the decision on when to
vaccinate is further complicated as severe immune sup-
pression is a contraindication to vaccination with live
vaccines such as the measles vaccine [34]. However,
those with symptomatic HIV infection but who are not
severely immuno compromised are considered for vacci-
nation [20].
There was also an association with lower risk of incom-
plete immunisation among children receiving breastfeed-
ing counselling than children in the control arm. Despite
the fact that this intervention did not prove particularly
effective in increasing the practice of exclusive breast-
feeding in South Africa (submitted) and even though the
mothers were not counselled on vaccines, there was a
general focus on child health in addition to the breast-
feeding in the intervention arm of the study which might
explain the positive impact on vaccination.
To have a good vaccination program, a well-functioning
health system is required [35], where both individual and
contextual factors are of importance for utilization of the
health services [36]. The very substantial differences in
Figure 2 Cumulative incomplete vaccination and untimely vaccination from birth to 6 months of age (including vaccination with BCG,
4 doses of oral polio vaccines, and 3 doses of pentavalent vaccines) . 1 Coverage: The line drops represent the proportion that has got all
the vaccines to that point, but does not get the given vaccine (e.g. if a child get all vaccines except the last pentavalent vaccine, the child will
add to the line drop at polio3/DTP3) 2 Timeliness: The line drops represent the proportion that has got all the vaccines to that point within their
recommended time ranges, but does not get the given vaccine within the recommended range (e.g. if a child get all vaccines within
recommend time except the DPT3 vaccine, the child will add to the line drop at third pentavalent) 3 Measles vaccine and booster vaccination
not included due to sub-optimal data quality
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Figure 3 Time when receiving the measles vaccine and booster vaccination with measles, DPT and oral polio presented with
histogram (must be interpreted with caution) . 1 The blue vertical lines indicate the recommended age for vaccination, while the red lines
on the measles vaccine indicate the outer ranges for the recommended age. 2 When the booster vaccine against measles was given at different
time from the booster against polio and DPT (3 cases), the time of the measles booster will be presented.
Table 2 Baseline characteristics of study participants presented with number (n) and percentages, determinants of
untimely vaccination, and determinants of incomplete vaccination at end of follow-up presented with hazard ratios












≤ 19 265 (23) 1 1
20 - 24 387 (34) 0.77 (0.57-1.0) 0.70 (0.47-1.1)
25 - 29 249 (22) 0.91 (0.68-1.2) 0.59 (0.41-0.85)
≥ 30 234 (21) 0.90 (0.65-1.2) 0.96 (0.66-1.4)
Marital status * *
Married or cohabiting 712 (63) 1 1
Single, widowed, separated or divorced 422 (37) 0.64 (0.51-0.81) 0.65 (0.45-0.95)
Gender of infant
Girl 568 (50) 1 1 1
Boy 559 (50) 1.3 (1.0-1.6) 1.2 (0.92-1.5) 0.95 (0.68-1.3)
Mother’s education *
Primary (0-7 years) 142 (11) 1 1
Secondary (8-11 years) 756 (59) 1.2 (0.80-1.7) 0.62 (0.40-0.96)
Higher (12 or above) 378 (30) 0.81 (0.53-1.2) 0.31 (0.19-0.53)
Socio economic wealth index * *
Least poor quintile 234 (21) 1 1
4th quintile 253 (22) 0.91 (0.56-1.5) 1.4 (0.70-3.0)
3rd quintile 223 (20) 1.1 (0.69-1.8) 2.2 (1.1-4.4)
2nd quintile 210 (18) 1.5 (1.0-2.4) 3.6 (1.8-7.0)
Poorest quintile 217 (19) 2.4 (1.6-3.6) 7.5 (4.0-14)
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vaccination coverage between the three sites in this study
are largely a reflection of the relative strengths and func-
tionality of the health systems in these three areas, as well
as the large differences in socio economic status [37].
Achieving good and timely vaccination coverage and elim-
inating the vast disparities between the different geogra-
phical areas will require both general developmental
interventions - concerning education, infrastructure and
communications - as well as health system strengthening.
The latter efforts will need to focus on good coverage by
health services, particularly at community and primary
levels with effective referral mechanisms, well-equipped
and organised clinics with short waiting times and effec-
tive integration of maternal and child health activities, as
well as good media promotion and campaigns [35,38].
Vaccination reminders are an effective strategy to improve
vaccination, particularly phone call reminders [39]. The
feasibility of instituting vaccination reminders should be
explored, given that possession and use of cell phones in
South Africa has increased dramatically in the recent past.
This study has some limitations. The time estimate of
the first measles vaccination is likely to be biased to
vaccination before 12 months because a question from the
last interview was missed out. Thus, the time distribution
of the measles vaccination must be interpreted with cau-
tion. Some of the last follow-up interviews were also done
too early to assess the booster vaccination, but this is likely
to have affected the estimates less than for the first
measles vaccine.
The children who died during follow-up might have
had different vaccination status compared to the surviv-
ing majority [40], but mortality was low and therefore
this is unlikely to have biased our estimates. Most of the
vaccination information was collected in the 24 weeks
interview and those who were not interviewed at that
point and did not provide sufficient vaccination informa-
tion in the other interviews visits might also have had a
different vaccination status. The proportion of partici-
pants with insufficient information to be assessed was
13%. These participants were more often from the poorer
areas, and thus the combined estimates might be slightly
lower than what has been presented in this paper. The
timeliness of vaccination in the few children who had
immunisation indicated as received but not dated in the
Table 2 Baseline characteristics of study participants presented with number (n) and percentages, determinants of
untimely vaccination, and determinants of incomplete vaccination at end of follow-up presented with hazard ratios
(HR) with 95% confidence interval assessed with a cluster adjusted Cox regression model (Continued)
Living area * * * *
Paarl 349 (31) 1 1 1 1
Rietvlei 305 (27) 3.8 (2.7-5.5) 3.3 (2.3-4.7) 7.4 (4.4-13) 7.2 (4.7-11)
Umlazi 480 (42) 1.7 (1.3-2.4) 1.6 (1.2-2.3) 1.9 (1.1-3.5) 2.2 (1.3-3.7)
Place of delivery * * *
Home 68 (6) 1 1 1
In health facility 1021 (94) 0.37 (0.26-0.54) 0.53 (0.38-0.74) 0.36 (0.20-0.64)
Health councelling * *
Normal 485 (43) 1 1 1
Additional peer-counselling 535 (47) 0.88 (0.56-1.4) 0.67 (0.35-1.28) 0.64 (0.49-0.83)
Intention to formula feed 117 (10) 0.74 (0.41-1.3) 0.40 (0.16-0.96) 0.39 (0.18-0.89)
Number of siblings * *
None 537 (47) 1 1 1
1 - 2 464 (41) 1.0 (0.84-1.3) 1.3 (1.04-1.7) 1.3 (0.97-1.7)
3 or above 130 (11) 1.4 (1.08-1.9) 2.2 (1.4-3.5) 1.7 (1.0-2.7)
Mother’s body mass index (BMI)
< 20 70 (8) 1 1
20 - 24.9 361 (39) 1.3 (0.76-2.1) 0.82 (0.44-1.5)
25 - 29.9 283 (31) 1.2 (0.69-2.2) 0.77 (0.40-1.5)
≥ 30 211 (23) 1.5 (0.88-2.5) 0.76 (0.43-1.3)
* Significantly associated variables (both categorised and socio-economy also uncategorised).
Interactions were checked and none were considered meaningful to include.
All factors are cluster adjusted.
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health card could be different from the majority where it
was dated. As there were only a few and that they had
similar baseline characteristics (data not shown), we
believe this has not biased our estimates markedly. Con-
traindications for vaccination were not assessed [41], but
this is relevant only in a few cases. It may be justified to
temporarily postpone vaccination in some few cases
when children are moderately or severely ill. Some chil-
dren may have been HIV-positive with severe immune
suppression, which is a contraindication for live vaccines
such as the measles vaccine and complicates the assess-
ment of coverage and timeliness [34,41]]. In this study,
many of the mothers in the intention to formula feed
arm were HIV-positive, but the number of infected chil-
dren is likely to be much less. As the Cox regression
model assessed timeliness with specific accepted time
ranges, there were several ties with equal time-to-event.
To improve model robustness, we used the exact partial-
likelihood method for handling ties. The study also has
several strengths compared to many studies assessing
vaccination; these include a prospective design, date
assessment of the vaccines, assessment of all recom-
mended vaccines, inclusion of different sites, and the use
of time-to-event analysis.
Conclusion
There are substantial differences in vaccination coverage
and timely vaccination between different geographical
areas in South Africa. There was a trend towards worse
vaccination coverage with the later vaccines in the vacci-
nation programme. To have adequate disease protection
and to aim for elimination of some of the diseases, there
is a need for continued efforts to improve vaccination
coverage and timeliness.
There is also a need for efforts and research to assess
whether general socio economic development as well as
strengthening of the health systems could improve vac-
cination coverage and reduce disparities between differ-
ent geographical areas and socio economic groups.
Additional material
Additional file 1: Figure S1: Study profile. Number of participants in
the different trial arms: Good Start Study (intention to formula feed) and
PROMISE-EBF study (intention to breastfeed) with its intervention and
control arms. The number of participants interviewed in the different
visits is given with proportion of the included participants in the
parenthesis. Cumulative proportion of lost-to-follow-up is also added in
brackets.
Additional file 2: Figure S2: Figure presenting age distribution
when the different vaccines are given for all the sites combined
(hazard plot). 1 The blue vertical lines indicate the recommended age
for vaccination (overlapping with red lines at birth for BCG and first polio
vaccine), while the red lines indicate the outer ranges for the
recommended age. The horizontal dotted lines represent coverage at
end of follow-up. 2 The labels on the x-axis indicate the outer ranges for
recommended vaccination age. One year of age is indicated as a scaling,
but is also the upper recommended age for the measles vaccine.
Additional file 3: Figure S3: Timing of the oral polio vaccine
(polio0) given at birth for each site presented with Kaplan-Meier
plots (inverse and cumulative). 1 The blue vertical lines indicate the
recommended age for vaccination (overlapping with red lines at birth for
BCG and first polio vaccine), while the red lines indicate the outer ranges
for the recommended age. The horizontal dotted lines represent
coverage at end of follow-up. 2 The labels on the x-axis indicate the
outer ranges for recommended vaccination age. One year of age is
indicated as a scaling, but is also the upper recommended age for the
measles vaccine. 3 Blue graphs line: Paarl; green graph line: Umlazi; red
graph line: Rietvlei.
Additional file 4: Figure S4: Timing of the BCG vaccine given at
birth for each site presented with Kaplan-Meier plots (inverse and
cumulative). 1 The blue vertical lines indicate the recommended age for
vaccination (overlapping with red lines at birth for BCG and first polio
vaccine), while the red lines indicate the outer ranges for the
recommended age. The horizontal dotted lines represent coverage at
end of follow-up. 2 The labels on the x-axis indicate the outer ranges for
recommended vaccination age. One year of age is indicated as a scaling,
but is also the upper recommended age for the measles vaccine. 3 Blue
graphs line: Paarl; green graph line: Umlazi; red graph line: Rietvlei.
Additional file 5: Figure S5: Timing of the second oral polio vaccine
(polio1) for each site presented with Kaplan-Meier plots (inverse
and cumulative). 1 The blue vertical lines indicate the recommended
age for vaccination (overlapping with red lines at birth for BCG and first
polio vaccine), while the red lines indicate the outer ranges for the
recommended age. The horizontal dotted lines represent coverage at
end of follow-up. 2 The labels on the x-axis indicate the outer ranges for
recommended vaccination age. One year of age is indicated as a scaling,
but is also the upper recommended age for the measles vaccine. 3 Blue
graphs line: Paarl; green graph line: Umlazi; red graph line: Rietvlei.
Additional file 6: Figure S6: Timing of the first pentavalent vaccine
(pentavalent1) for each site presented with Kaplan-Meier plots
(inverse and cumulative). 1 The blue vertical lines indicate the
recommended age for vaccination (overlapping with red lines at birth for
BCG and first polio vaccine), while the red lines indicate the outer ranges
for the recommended age. The horizontal dotted lines represent
coverage at end of follow-up. 2 The labels on the x-axis indicate the
outer ranges for recommended vaccination age. One year of age is
indicated as a scaling, but is also the upper recommended age for the
measles vaccine. 3 Blue graphs line: Paarl; green graph line: Umlazi; red
graph line: Rietvlei.
Additional file 7: Figure S7: Timing of the third oral polio vaccine
(polio2) for each site presented with Kaplan-Meier plots (inverse
and cumulative). 1 The blue vertical lines indicate the recommended
age for vaccination (overlapping with red lines at birth for BCG and first
polio vaccine), while the red lines indicate the outer ranges for the
recommended age. The horizontal dotted lines represent coverage at
end of follow-up. 2 The labels on the x-axis indicate the outer ranges for
recommended vaccination age. One year of age is indicated as a scaling,
but is also the upper recommended age for the measles vaccine. 3 Blue
graphs line: Paarl; green graph line: Umlazi; red graph line: Rietvlei.
Additional file 8: Figure S8: Timing of the second pentavalent
vaccine (pentavalent2) for each site presented with Kaplan-Meier
plots (inverse and cumulative). 1 The blue vertical lines indicate the
recommended age for vaccination (overlapping with red lines at birth for
BCG and first polio vaccine), while the red lines indicate the outer ranges
for the recommended age. The horizontal dotted lines represent
coverage at end of follow-up. 2 The labels on the x-axis indicate the
outer ranges for recommended vaccination age. One year of age is
indicated as a scaling, but is also the upper recommended age for the
measles vaccine. 3 Blue graphs line: Paarl; green graph line: Umlazi; red
graph line: Rietvlei.
Additional file 9: Figure S9: Timing of the fourth oral polio vaccine
(polio3) for each site presented with Kaplan-Meier plots (inverse
and cumulative). 1 The blue vertical lines indicate the recommended
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age for vaccination (overlapping with red lines at birth for BCG and first
polio vaccine), while the red lines indicate the outer ranges for the
recommended age. The horizontal dotted lines represent coverage at
end of follow-up. 2 The labels on the x-axis indicate the outer ranges for
recommended vaccination age. One year of age is indicated as a scaling,
but is also the upper recommended age for the measles vaccine. 3 Blue
graphs line: Paarl; green graph line: Umlazi; red graph line: Rietvlei.
Additional file 10: Figure S10: Timing of the third pentavalent
vaccine (pentavalent3) for each site presented with Kaplan-Meier
plots (inverse and cumulative). 1 The blue vertical lines indicate the
recommended age for vaccination (overlapping with red lines at birth for
BCG and first polio vaccine), while the red lines indicate the outer ranges
for the recommended age. The horizontal dotted lines represent
coverage at end of follow-up. 2 The labels on the x-axis indicate the
outer ranges for recommended vaccination age. One year of age is
indicated as a scaling, but is also the upper recommended age for the
measles vaccine. 3 Blue graphs line: Paarl; green graph line: Umlazi; red
graph line: Rietvlei.
Abbreviations
BCG: Bacillus Calmette-Guérin; CI: confidence interval; DTP: diphtheria,
tetanus and pertussis; EPI: Expanded Programme on Immunization; HR:
hazard ratio; HBV: hepatitis B; HiB: Haemophilus influenza type B; WHO:
World Health Organisation.
Acknowledgements
We thank the data collectors, all the families who contributed to this study,
and Johnny Nare Rakgole, Zainab Waggie and Charles Shey Wiysonge for
information about the South African EPI.
Thanks also to the PROMISE-EBF Study Group:
Steering Committee: Thorkild Tylleskär, Philippe van de Perre, Eva-Charlotte
Ekström, Nicolas Meda, James K Tumwine, Chipepo Kankasa, Debra Jackson
Participating countries and investigators:
Norway: Thorkild Tylleskär, Ingunn MS Engebretsen, Lars T Fadnes, Eli Fjeld
Falnes, Knut Fylkesnes, Jørn Klungsøyr, Anne Nordrehaug-Åstrøm, Øystein
Evjen Olsen, Bjarne Robberstad, Halvor Sommerfelt
France: Philippe Van de Perre
Sweden: Eva-Charlotte Ekström, Barni Nor
Burkina Faso: Nicolas Meda, Hama Diallo, Thomas Ouedrago, Jeremi
Rouamba, Bernadette Traoré Germain Traoré, Emmanuel Zabsonré
Uganda: James K. Tumwine, Caleb Bwengye, Charles Karamagi, Victoria
Nankabirwa, Jolly Nankunda, Grace Ndeezi, Margaret Wandera
Zambia: Chipepo Kankasa, Mary Katepa-Bwalya, Chafye Siuluta, Seter Siziya
South Africa: Debra Jackson, Mickey Chopra, Mark Colvin, Tanya Doherty, Carl
Lombard, Ameena E Goga, Lungiswa Nkonki, David Sanders, Sonja
Swanevelder, Wanga Zembe
(Country PI first, others in alphabetical order of surname)
Funding
The study was part of the European Union-funded project PROMISE-EBF
(contract no INCO-CT 2004-003660, http://www.promiseresearch.org). It was
also financially supported through the Swedish/South Africa Cooperation
and the South African National Research Foundation (NRF) and Centers for
Disease Control & Prevention South Africa/PEPFAR.
LTF, IMSE, HS and TT were employed and funded by the University of
Bergen. WZ was employed and funded by Medical Research Council, South
Africa. DS and DJ were employed and funded by University of the Western
Cape. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Author details
1Centre for International Health, University of Bergen, Norway. 2School of
Public Health, University of Western Cape, South Africa. 3Medical Research
Council, South Africa. 4Division of Infectious Disease Control, Norwegian
Institute of Public Health, Norway.
Authors’ contributions
LTF: design, analysis and writing. DJ, WZ, DS: design, implementation and
co-writing. IMSE, HS, TT: design, analysis and co-writing. The PROMISE-EBF
Study Group: design and implementation. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 February 2011 Accepted: 27 May 2011
Published: 27 May 2011
References
1. Grant CC, Roberts M, Scragg R, Stewart J, Lennon D, Kivell D, Ford R,
Menzies R: Delayed immunisation and risk of pertussis in infants:
unmatched case-control study. Brit Med J 2003, 326(7394):852-853.
2. Kolos V, Menzies R, McIntyre P: Higher pertussis hospitalization rates in
indigenous Australian infants, and delayed vaccination. Vaccine 2007,
25(4):588-590.
3. Heininger U, Zuberbuhler M: Immunization rates and timely
administration in pre-school and school-aged children. Eur J Pediatr 2006,
165(2):124-129.
4. von Kries R, Bohm O, Windfuhr A: Haemophilus influenzae b-vaccination:
the urgency for timely vaccination. Eur J Pediatr 1997, 156(4):282-287.
5. The measles epidemic. The problems, barriers, and recommendations.
The National Vaccine Advisory Committee. JAMA 1991,
266(11):1547-1552.
6. Breiman RF, Streatfield PK, Phelan M, Shifa N, Rashid M, Yunus M: Effect of
infant immunisation on childhood mortality in rural Bangladesh: analysis
of health and demographic surveillance data. Lancet 2004,
364(9452):2204-2211.
7. Akmatov MK, Kretzschmar M, Kramer A, Mikolajczyk RT: Timeliness of
vaccination and its effects on fraction of vaccinated population. Vaccine
2008, 26(31):3805-3811.
8. Dayan GH, Shaw KM, Baughman AL, Orellana LC, Forlenza R, Ellis A, Chaui J,
Kaplan S, Strebel P: Assessment of delay in age-appropriate vaccination
using survival analysis. Am J Epidemiol 2006, 163(6):561-570.
9. Clark A, Sanderson C: Timing of children’s vaccinations in 45 low-income
and middle-income countries: an analysis of survey data. Lancet 2009,
373(9674):1543-1549.
10. Luman ET, Barker LE, Shaw KM, McCauley MM, Buehler JW, Pickering LK:
Timeliness of childhood vaccinations in the United States - Days
undervaccinated and number of vaccines delayed. Jama-J Am Med Assoc
2005, 293(10):1204-1211.
11. Fadnes LT, Nankabirwa V, Sommerfelt H, Tylleskar T, Tumwine JK,
Engebretsen IM: Is vaccination coverage a good indicator of age-
appropriate vaccination? A prospective study from Uganda. Vaccine
2011, 29(19):3564-3570.
12. Shann F, Nohynek H, Scott JA, Hesseling A, Flanagan KL: Randomized trials
to study the nonspecific effects of vaccines in children in low-income
countries. Pediatr Infect Dis J 2010, 29(5):457-461.
13. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, Benn CS, Jensen H: Oral
polio vaccination and low case fatality at the paediatric ward in Bissau,
Guinea-Bissau. Vaccine 2004, 22(23-24):3014-3017.
14. Ndiritu M, Cowgill KD, Ismail A, Chiphatsi S, Kamau T, Fegan G, Feikin DR,
Newton CR, Scott JA: Immunization coverage and risk factors for failure
to immunize within the Expanded Programme on Immunization in
Kenya after introduction of new Haemophilus influenzae type b and
hepatitis b virus antigens. BMC Public Health 2006, 6(132).
15. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P,
Campbell H, Walker CF, Cibulskis R, et al: Global, regional, and national
causes of child mortality in 2008: a systematic analysis. Lancet 2010,
375(9730):1969-1987.
16. WHO and UNICEF concerned about measles outbreak in Eastern and
Southern Africa. [http://www.unicef.org/media/media_54018.html].
17. Nankunda J, Tylleskar T, Ndeezi G, Semiyaga N, Tumwine JK: Establishing
individual peer counselling for exclusive breastfeeding in Uganda:
implications for scaling-up. Matern Child Nutr 2010, 6(1):53-66.
18. National Department of Health South Africa: The national HIV and syphilis
prevalence survey South Africa 2007. Pretoria, South Africa: National
Department of Health 2007.
19. Jackson DJ, Chopra M, Doherty TM, Colvin MS, Levin JB, Willumsen JF,
Goga AE, Moodley P: Operational effectiveness and 36 week HIV-free
Fadnes et al. BMC Public Health 2011, 11:404
http://www.biomedcentral.com/1471-2458/11/404
Page 10 of 11
survival in the South African programme to prevent mother-to-child
transmission of HIV-1. AIDS 2007, 21(4):509-516.
20. The South African EPI (EPI-SA) schedule and method of vaccine
administration. [http://www.savic.ac.za].
21. Laubereau B, Hermann M, Schmitt HJ, Weil J, von Kries R: Detection of
delayed vaccinations: a new approach to visualize vaccine uptake.
Epidemiol Infect 2002, 128(2):185-192.
22. Howe LD, Hargreaves JR, Huttly SR: Issues in the construction of wealth
indices for the measurement of socio-economic position in low-income
countries. Emerg Themes Epidemiol 2008, 5:3.
23. Arevshatian L, Clements C, Lwanga S, Misore A, Ndumbe P, Seward J,
Taylor P: An evaluation of infant immunization in Africa: is a
transformation in progress? Bull World Health Organ 2007, 85(6):449-457.
24. World Health Organization: State of the world’s vaccines and
immunization., 3 2009 [http://www.who.int/immunization/sowvi/en/].
25. Smith PJ, Nuorti JP, Singleton JA, Zhao Z, Wolter KM: Effect of vaccine
shortages on timeliness of pneumococcal conjugate vaccination: results
from the 2001-2005 National Immunization Survey. Pediatrics 2007,
120(5):e1165-1173.
26. Daskalaki I, Spain CV, Long SS, Watson B: Implementation of rotavirus
immunization in Philadelphia, Pennsylvania: high levels of vaccine
ineligibility and off-label use. Pediatrics 2008, 122(1):e33-38.
27. Biellik R, Madema S, Taole A, Kutsulukuta A, Allies E, Eggers R, Ngcobo N,
Nxumalo M, Shearley A, Mabuzane E, et al: First 5 years of measles
elimination in southern Africa: 1996-2000. Lancet 2002,
359(9317):1564-1568.
28. Sudfeld CR, Navar AM, Halsey NA: Effectiveness of measles vaccination
and vitamin A treatment. Int J Epidemiol 2010, 39(Suppl 1):i48-55.
29. Polio vaccines and polio immunization in the pre-eradication era: WHO
position paper. Wkly Epidemiol Rec 2010, 85(23):213-228.
30. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL:
Measles eradication: is it in our future? Am J Public Health 2000,
90(10):1521-1525.
31. Stittelaar KJ, de Swart RL, Osterhaus AD: Vaccination against measles: a
neverending story. Expert Rev Vaccines 2002, 1(2):151-159.
32. Dai B, Chen ZH, Liu QC, Wu T, Guo CY, Wang XZ, Fang HH, Xiang YZ:
Duration of immunity following immunization with live measles vaccine:
15 years of observation in Zhejiang Province, China. Bull World Health
Organ 1991, 69(4):415-423.
33. Strebel P, Cochi S, Grabowsky M, Bilous J, Hersh BS, Okwo-Bele JM,
Hoekstra E, Wright P, Katz S: The unfinished measles immunization
agenda. J Infect Dis 2003, 187(Suppl 1):S1-7.
34. World Health Organization: Measles Vaccines: WHO Position Paper. Weekly
epidemiological record 2009, 84:349-360.
35. Rwashana AS, Williams DW, Neema S: System dynamics approach to
immunization healthcare issues in developing countries: a case study of
Uganda. Health Informatics J 2009, 15(2):95-107.
36. Andersen RM: National health surveys and the Behavioral Model of
Health Services Use. Med Care 2008, 46(7):647-653.
37. Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D: The health and
health system of South Africa: historical roots of current public health
challenges. Lancet 2009, 374(9692):817-834.
38. Ndiritu M, Cowgill KD, Ismail A, Chiphatsi S, Kamau T, Fegan G, Feikin DR,
Newton CRJC, Scott JAG: Immunization coverage and risk factors for
failure to immunize within the Expanded Programme on Immunization
in Kenya after introduction of new Haemophilus influenzae type b and
hepatitis b virus antigens. BMC Public Health 2006, 6.
39. Jacobson VJ, Szilagyi P: Patient reminder and patient recall systems to
improve immunization rates. Cochrane Database Syst Rev 2005,
CD003941(3).
40. Jensen H, Benn CS, Lisse IM, Rodrigues A, Andersen PK, Aaby P: Survival
bias in observational studies of the impact of routine immunizations on
childhood survival. Trop Med Int Health 2007, 12(1):5-14.
41. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK: General
recommendations on immunization: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006,
55(RR-15):1-48.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/11/404/prepub
doi:10.1186/1471-2458-11-404
Cite this article as: Fadnes et al.: Vaccination coverage and timeliness in
three South African areas: a prospective study. BMC Public Health 2011
11:404.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fadnes et al. BMC Public Health 2011, 11:404
http://www.biomedcentral.com/1471-2458/11/404
Page 11 of 11
